Drug
[18F]-APN-1607
[18F]-APN-1607 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
2
50%
Ph early_phase_1
1
25%
Ph phase_2
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Other(2)
Detailed Status
unknown2
Recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Early Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)
Trials by Status
recruiting125%
completed125%
unknown250%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_3
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
NCT07422857
completedphase_3
[18F]APN-1607 PET in Subjects With AD Compared to HC
NCT05542953
unknownearly_phase_1
Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients
NCT05043675
unknownphase_2
Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
NCT04141150
Clinical Trials (4)
Showing 4 of 4 trials
NCT07422857Phase 3
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
NCT05542953Phase 3
[18F]APN-1607 PET in Subjects With AD Compared to HC
NCT05043675Early Phase 1
Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients
NCT04141150Phase 2
Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4